There's not much development cost left. Oral Relistor, that's it. Most cost left will be commercialization cost. SLXP is the best choice for PGNX. Relistor is a specialty pharma product, not big pharma product. PGNX wasn't in strong position to demand better term.
Market Data 
Markets 
AI
